News

Spotlight:

November 10, 2023

Costimulatory bispecifics bring new biology to T cell engagers

Two T cell engaging bispecific antibodies may be better than one when it comes to driving activation of T cells against tumors, according to an emerging trend across two of the fall’s major conferences: the American Society of Hematology and Society for Immunotherapy of Cancer.

Read More

Press Releases

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

EvolveImmune Therapeutics Announces Initiation of Dosing in a Phase 1 Trial of EVOLVE104 in Patients with Solid Tumors

EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation

EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer

EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors

EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

2023 BioCT Entrepreneur of the Year Dr. Stephen Bloch Serial Entrepreneur

EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences